{
    "nct_id": "NCT03459222",
    "official_title": "A Phase 1/2 Study of Relatlimab (Anti-LAG-3 Monoclonal Antibody) Administered in Combination With Both Nivolumab (Anti-PD-1 Monoclonal Antibody) and BMS-986205 (IDO1 Inhibitor) or in Combination With Both Nivolumab and Ipilimumab (Anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors",
    "inclusion_criteria": "* Histologic or cytologic confirmation of select incurable solid malignancies that are advanced (metastatic and/or unresectable), with measurable disease per RECIST v1.1\n* Available tumor tissue for biomarker analysis\n* Eastern Cooperative Oncology Group Performance Status (ECOG) status of 0 or 1\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Known or suspected central nervous system (CNS) metastases or with the CNS as the only site of active disease\n* History of interstitial lung disease / pneumonitis\n* Prior malignancy active within the previous 2 years except for locally curable cancers that have been cured, such as basal or squamous cell skin cancer\n* Encephalitis, meningitis, or uncontrolled seizures in the year prior to informed consent\n\nOther protocol-defined inclusion/exclusion criteria apply",
    "miscellaneous_criteria": ""
}